Last updated: 11/04/2018 10:26:17

A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers

GSK study ID
RH01418
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
Trial description: Bioequivalence study to confirm that a NTS with a polyisobutylene (PIB) adhesive from an alternative supplier delivers the same nicotine blood profile as that of the currently approved NTS with a polyisobutylene adhesive from the current supplier.
Primary purpose:
Other
Trial design:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Area under the curve from time 0 to the last quantifiable sample, AUC(0-t)

Timeframe: Baseline to 32 hours

Maximum Measured Plasma Concentration (Cmax)

Timeframe: Baseline to 32 hours

Secondary outcomes:

Area under the concentration time curve between zero and infinity, AUC (0-inf)

Timeframe: Baseline to 32 hours

Time to Maximum Plasma Concentration (Tmax)

Timeframe: Baseline to 32 hours

Plasma half-life (t1/2)

Timeframe: Baseline to 32 hours

Rate of elimination (Kel)

Timeframe: Baseline to 32 hours

Interventions:
  • Drug: nicotine
  • Enrollment:
    40
    Primary completion date:
    2012-31-03
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Smoking
    Product
    nicotine
    Collaborators
    Not applicable
    Study date(s)
    March 2012 to March 2012
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    19 - 55 years
    Accepts healthy volunteers
    Yes
    • BMI 19-27 kg/m2
    • smokes >10 cigarettes per day for preceeding 6 months
    • inability to stop smoking during study

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    Celerion NEBRASKA
    Lincoln, NE, United States, 68502
    Status
    Recruiting

    Study documents

    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2012-31-03
    Actual study completion date
    2012-31-03

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website